Patents by Inventor Mark M. Gleason
Mark M. Gleason has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20180250293Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.Type: ApplicationFiled: November 21, 2017Publication date: September 6, 2018Inventors: Penglie ZHANG, Andrew M.K. PENNELL, John J. Kim WRIGHT, Wei CHEN, Manmohan R. LELETI, Yandong LI, Lianfa LI, Yuan XU, Mark M. GLEASON, Yibin ZENG, Kevin Lloyd GREENMAN
-
Publication number: 20160296517Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.Type: ApplicationFiled: February 23, 2016Publication date: October 13, 2016Inventors: Penglie ZHANG, Andrew M. K. Pennell, John J. Kim Wright, Wei Chen, Manmohan R. Leleti, Yandong Li, Lianfa Li, Yuan Xu, Mark M. Gleason, Yibin Zeng, Kevin Lloyd Greenman
-
Patent number: 9296740Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.Type: GrantFiled: February 22, 2013Date of Patent: March 29, 2016Assignee: ChemoCentryx, Inc.Inventors: Penglie Zhang, Andrew M. K. Pennell, John J. Kim Wright, Wei Chen, Manmohan R. Leleti, Yandong Li, Lianfa Li, Yuan Xu, Mark M. Gleason, Yibin Zeng, Kevin Lloyd Greenman
-
Patent number: 8853202Abstract: Compounds having formula I, or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a pharmaceutically acceptable excipient.Type: GrantFiled: May 12, 2010Date of Patent: October 7, 2014Assignee: ChemoCentryx, Inc.Inventors: Xi Chen, Dean R. Dragoli, Pingchen Fan, Mark M. Gleason, Juan C. Jaen, Lianfa Li, Jeffrey P. McMahon, Jay Powers, Yibin Zeng, Penglie Zhang, Junfa Fan
-
Publication number: 20130338157Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.Type: ApplicationFiled: February 22, 2013Publication date: December 19, 2013Applicant: Chemocentryx, Inc.Inventors: Penglie Zhang, Andrew M.K. Pennell, John J. Kim Wright, Wei Chen, Manmohan R. Leleti, Yandong Li, Lianfa Li, Yuan Xu, Mark M. Gleason, Yibin Zeng, Kevin Lloyd Greenman
-
Patent number: 8288373Abstract: Compounds having formula I, or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a pharmaceutically acceptable excipient.Type: GrantFiled: November 4, 2009Date of Patent: October 16, 2012Assignee: Chemocentryx, Inc.Inventors: Xi Chen, Pingchen Fan, Mark M. Gleason, Juan C. Jaen, Lianfa Li, Jeffrey P. McMahon, Jay Powers, Yibin Zeng, Penglie Zhang
-
Publication number: 20110098308Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.Type: ApplicationFiled: July 1, 2010Publication date: April 28, 2011Applicant: Chemocentryx, Inc.Inventors: Penglie Zhang, Andrew M.K. Pennell, John J. Kim Wright, Wei Chen, Manmohan R. Leleti, Yandong Li, Lianfa Li, Yuan Xu, Mark M. Gleason, Yibin Zeng, Kevin Lloyd Greenman
-
Publication number: 20110014121Abstract: Compounds having formula I, or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a pharmaceutically acceptable excipient.Type: ApplicationFiled: March 29, 2010Publication date: January 20, 2011Applicant: ChemoCentryx, Inc.Inventors: Xi Chen, Pingchen Fan, Mark M. Gleason, Juan C. Jaen, Lianfa Li, Jeffrey P. McMahon, Jay Powers, Yibin Zeng, Penglie Zhang
-
Publication number: 20100311712Abstract: Compounds having formula I, or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a pharmaceutically acceptable excipient.Type: ApplicationFiled: May 12, 2010Publication date: December 9, 2010Applicant: ChemoCentryx, Inc.Inventors: Xi CHEN, Dean R. DRAGOLI, Pingchen FAN, Mark M. GLEASON, Juan C. JAEN, Lianfa LI, Jeffrey P. MCMAHON, Jay POWERS, Yibin ZENG, Penglie ZHANG, Junfa FAN
-
Patent number: 7777035Abstract: Methods are provided for the synthesis of 1-[4-(substituted phenyl)-piperazin-1-yl ] -2- [3-(1H-imidazol-2-yl)-pyrazolo [3,4-b]pyridin-1-yl]-ethanone compounds via construction of the imidazole portion onto the corresponding aldehyde or nitrile compounds.Type: GrantFiled: May 22, 2007Date of Patent: August 17, 2010Assignee: Chemocentryx, Inc.Inventors: Penglie Zhang, Andrew M. K. Pennell, John J. Kim Wright, Wei Chen, Manmohan R. Leleti, Yandong Li, Lianfa Li, Yuan Xu, Mark M. Gleason, Yibin Zeng, Kevin Lloyd Greenman
-
Publication number: 20100150831Abstract: Compounds having formula I, or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a pharmaceutically acceptable excipient.Type: ApplicationFiled: November 4, 2009Publication date: June 17, 2010Applicant: ChemoCentryx, Inc.Inventors: Xi Chen, Pingchen Fan, Mark M. Gleason, Juan C. Jaen, Lianfa Li, Jeffrey P. McMahon, Jay Powers, Yibin Zeng, Penglie Zhang
